NSE/DRREDDY

DRREDDYDr. Reddy's Laboratories Ltd

Healthcare · NSE

₹1,235.7+1.17%

52-wk low52-WEEK RANGE52-wk high

₹1,094.05+12.9% from low ·-9.3% from high₹1,362.7

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

DRREDDY+12.95% · 1Y

Range high ₹1,379.7Range low ₹1,061.65Latest ₹1,235.7252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareDrug Manufacturers - Specialty & GenericLargecapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite38/100

Performance

Low

Hasn't fared well — amongst the weak performers.

· 52w return +5.0%
· Below 200-DMA (-1.8%) — downtrend

Valuation

Medium

Valuation close to the sector median.

· P/E 18.2 vs sector median 37.8 — 52% cheaper
· PEG 3.61 — pricey relative to growth

Growth

Low

Lagging the market in growth.

· Revenue YoY +4.4% — slow
· Profit YoY -14.3% — earnings slipping

Profitability

High

Showing good signs of profitability & efficiency.

· ROE 16.1%
· Net margin 17.4% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(66/100)

Durability

79/100

Financially resilient — strong quality + solvency profile.

Show 4 drivers

Piotroski F-score5/9 (56pt)
Altman Z" score6.14 (100pt)
Debt/Equity0.18 (100pt)
ROE16.1% (64pt)

Valuation

70/100

Fairly priced — not a bargain, not stretched.

Show 5 drivers

P/E vs sector (18.2 / 37.8)48% (100pt)
PEG3.61 (14pt)
P/B2.76 (100pt)
Dividend yield0.65% (16pt)
EV/EBITDA12.0 (70pt)

Momentum

50/100

Momentum is muted; trend is unclear or rolling over.

Show 5 drivers

52w change+5.0% (51pt)
DMA-trend alignmentdown (25pt)
RSI (14)47.5 (60pt)
Price vs 200-DMA-1.7% (50pt)
MACD regimebullish cross (95pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)18.17

UNDERVALUED

CheapestP/E 18.2 at 8th %ile of sector — cheaper than 92% of peers.Most expensive

P/B2.76

UNDERVALUED

CheapestP/B 2.76 at 17th %ile of sector.Most expensive

EV/EBITDA12.00

FAIR

Monthly seasonality

Avg monthly return over 11 years · historical — not a forecast

Best: Jun +4.68% · Worst: Jan -2.70%

Jan

-2.7%

36% win

Feb

-1.9%

33% win

Mar

+1.0%

58% win

Apr

+4.2%

67% win

May

-0.7%

55% win

Jun

+4.7%

Monthly return distribution

Distribution of 135 monthly returns

Mean

+0.76%

Median

+0.57%

Std dev

7.43%

Best

+26.1%

Worst

-27.3%

% positive

54%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 4

Lean balance sheet (D/E 0.18)
Low leverage means earnings are less sensitive to rate cycles
Strong net margin (17.4%)
High margin indicates pricing power + operating efficiency
Bankruptcy risk low (Altman Z″ 6.14)
Z″ above 2.60 sits squarely in the 'safe' zone
Top quartile ROE in Healthcare
Rank 6 of 24 peers

WEAKNESSES · 0

No material weaknesses flag from the numbers

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 1

Profit contracting sharply (-14.3% YoY)
Double-digit earnings decline pressures valuation compression

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+1.2%

+0.3%

-4.4%

+2.4%

-0.7%

+11.5%

+6.6%

10Y

+7.2%

Fundamentals

VALUATION

Market cap

₹1,02,626 Cr

P/E (TTM)

18.2

P/E (fwd)

22.4

next 12m

P/B

2.76

EV/EBITDA

12.0

Book value

₹447.25

per share

PROFITABILITY · QUALITY

ROE

16.1%

ROCE

—

Net margin

17.4%

Op margin

16.4%

Gross margin

55.2%

D/E

0.18

GROWTH · MARKET

Rev YoY

+4.4%

Profit YoY

-14.3%

Div yield

0.65%

Payout

11.8%

52w change

+5.0%

Beta

0.30

defensive

Pros and cons

Auto-derived from ratios · not a buy/sell recommendation

PROS · 3

+Trading at -52.0% vs sector median P/EP/E 18.2 vs Healthcare median 37.8 — relative value on earnings
+3-year profit CAGR of 33.9%Consistently compounding earnings — the Buffett playbook
+Nearly debt-free (D/E 0.18)Low financial risk — funds growth from internal accruals, resilient in downturns

CONS · 0

No material concerns surface from the ratios alone — still layer qualitative research.

Sector-relative context

Healthcare · 24 peers

P/E (TTM)

This stock

18.17

Sector median

37.85

Rank 2/24 (96th %ile)

ROE

This stock

16.1%

Sector median

13.8%

Rank 19/24 (25th %ile)

P/B

This stock

2.76

Sector median

5.81

Rank 4/24 (88th %ile)

Quality score · Piotroski F-score

5 / 9

Decent quality — clears Piotroski bar

✓Profitable (positive net income)· Most basic check — company makes money
✓Positive return on assets· Assets generate returns
✓Positive operating cash flow· Profits are backed by real cash, not accruals
✓Operating CF exceeds net profit· Healthy cash conversion — no aggressive revenue recognition
✗Long-term debt decreased YoY· Deleveraging — lower refinancing risk
✗ROA improved YoY· Getting more productive with the asset base
✗Operating margin expanded YoY· Pricing power or cost discipline
✗

Forensic score · Altman Z″ (emerging markets)

Bankruptcy-risk predictor · 1995 Altman emerging-market revision

SAFE6.14

Z″ = 6.14 — well inside the SAFE zone. Low bankruptcy risk signal across liquidity, profitability and solvency inputs.

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.282	×6.56	1.850
Retained Earnings / Total Assets (B)	0.600	×3.26	1.956
EBIT / Total Assets (C)	0.110	×6.72	0.741
Book Equity / Total Liabilities (D)	1.518	×1.05	1.594

Zones: Z″ ≥ 2.60 safe · 1.10–2.60 grey · < 1.10 distress. All four inputs derived from latest annual filing.

Analyst consensus

38 analysts · HOLD

Target mean

₹1318.45

Target high

₹1615.00

Target low

₹1024.00

Upside vs today

+7.0%

Street consensus target is +7.0% vs current price. Consensus is a lagging sentiment read, not a forecast.

Company + balance sheet snapshot

Industry

Drug Manufacturers - Specialty & Generic

Employees

27,811

Shares out

83.3

Revenue (TTM)

₹34,583 Cr

EBITDA

₹8,479 Cr

Total debt

₹6,773 Cr

Cash

₹8,259 Cr

Net debt

₹-1,486 Cr

Quarterly results

Last 6 quarters · ₹ Cr (Screener.in-grade depth)

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q3	2025-Q4
Revenue	—	8,359	8,506	8,545	8,805	8,727
Operating profit	—	1,871	1,735	1,684	1,787	1,433
OPM %	—	22.4%	20.4%	19.7%	20.3%	16.4%

Annual P&L

Last 4 years · ₹ Cr · all line items

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	21,439	24,588	27,916	32,554
Operating profit	3,592	5,905	6,531	7,201
OPM %	16.8%	24.0%	23.4%	22.1%
Other income	-363	156	600	492

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
DRREDDYTHIS Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%
ALKEM Alkem Laboratories Limited	₹5,582	+11.6%	67,578	28.5	5.06	17.8%	0.17	+2.3%

ASK AXEL

Dig deeper into DRREDDY

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for DRREDDY — all in one sourced reply.

Ask free in chat

Run these tools on DRREDDY

Historical return →

"If I had bought DRREDDY in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on DRREDDY

Brokerage + charges →

All-in cost for trading DRREDDY

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	14.27	14.77	+3.5%
-2q	17.20	17.87	+3.9%
-3q	18.28	17.02	-6.9%
-4q	17.74	19.84	+11.8%

Date	Amount
2025-07-10	₹8.00
2024-07-16	₹8.00
2023-07-11	₹8.00
2022-07-11	₹6.00
2021-07-09	₹5.00
2020-07-13	₹5.00
2019-07-15	₹4.00
2018-07-16	₹4.00
2017-07-17	₹4.00
2016-07-18	₹4.00

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	83	83	83	83
Reserves	17,571	21,559	26,526	31,579
Borrowings	3,385	1,347	2,002	4,677
Other liabilities	83	129	278	214
Total liabilities	29,283	32,185	38,752	49,299
Fixed assets	6,217	6,646	7,689	9,776
CWIP	1,339	996	1,446	2,484
Investments	367	66	106	1,039
Other assets	22	13	89	22
Total assets	29,283	32,185	38,752	49,299

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	2,811	5,888	4,543	4,643
CF Investing	-2,639	-4,137	-4,028	-5,808
CF Financing	-242	-2,686	-376	1,891
Net cash flow	3	-907	133	749
Free cash flow	906	4,001	1,800	1,203

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	22.1%	23.4%	24.0%	16.8%
Net margin %	17.4%	19.9%	18.3%	11.0%
ROE %	19.4%	23.1%	22.9%	13.3%
ROCE %	24.5%	28.5%	28.1%	15.8%
Debt / Equity	0.15	0.08	0.06	0.19
Dividend payout %	12%	12%	11%	18%
Interest coverage	28.1×	43.0×	43.3×	34.7×
Revenue growth YoY	+16.6%	+13.5%	+14.7%	—
Profit growth YoY	+1.5%	+23.6%	+91.2%	—

DRREDDYDr. Reddy's Laboratories Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Peer comparison · Healthcare

Ask Axel about DRREDDY

Recent news

Dig deeper into DRREDDY

Run these tools on DRREDDY

Technical snapshot

Earnings history + surprises

Dividends + splits history

Recent news

Stock scorecard

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare